Skip to main
DNTH

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics is experiencing positive developments indicated by a recent increase in their target price, now set at $46, driven by higher net cash and a reduced share count. The company’s clinical pipeline, particularly with the advancements in DNTH103, shows promise in differentiating their product offerings in the competitive landscape of complement therapeutics. As the company progresses in its clinical trials, there is an overall positive sentiment regarding its capabilities to address severe autoimmune and inflammatory diseases, reinforcing a favorable outlook for its financial trajectory.

Bears say

Dianthus Therapeutics Inc. may face significant challenges in advancing its pipeline due to potential funding shortfalls that could hinder its operations. The company has removed an assumed offering for fiscal year 2028 and has subsequently lowered its share count projections for fiscal year 2025, indicating financial constraints. These developments suggest a weak financial position that could impede the company's progress in developing its therapeutics.

DNTH has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 8 analysts, DNTH has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.